ArticleFrontiers in microbiology2021
Comparison of CRISPR-Cas Immune Systems in Healthcare-Related Pathogens.
Article in Frontiers in microbiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 34 citations in OpenAlex.
- Multiplex RPA-CRISPR/Cas12a Assay for Rapid Detection of Class D OXA-Type Carbapenem-ResistantBiosensors · 2026Article
- CRISPR-Cas13a as a next-generation tool for rapid and precise plant RNA virus diagnostics.Plant methods · 2025Review
- Reinvigorating AMR resilience: leveraging CRISPR-Cas technology potentials to combat the 2024 WHO bacterial priority pathogens for enhanced global health security-a systematic review.Tropical medicine and health · 2025Review
- Molecular epidemiological study of Pseudomonas aeruginosa strains isolated from hospitals in Brazil by MLST and CRISPR/Cas system analysis.Molecular genetics and genomics : MGG · 2025Article
- Genomic analysis of theFrontiers in microbiology · 2025Article
- CRISPR-Cas systems in enterococci.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2024Review
- Article
- The application of CRISPR-Cas system inHeliyon · 2024Article
- Virophages, Satellite Viruses, Virophage Replication and Its Effects and Virophage Defence Mechanisms for Giant Virus Hosts and Giant Virus Defence Systems against Virophages.International journal of molecular sciences · 2024Review
- Exploring the Interplay of the CRISPR-CAS System with Antibiotic Resistance inMedicina (Kaunas, Lithuania) · 2024Article
- Sub-MIC antibiotics increased the fitness cost of CRISPR-Cas inFrontiers in microbiology · 2024Article
- CRISPR-Based Gene Editing inPharmaceuticals (Basel, Switzerland) · 2023Review
- Analysis of CRISPR/Cas Genetic Structure, Spacer Content and Molecular Epidemiology in BrazilianPathogens (Basel, Switzerland) · 2023Article
- Analysis of bacterial pangenomes reduces CRISPR dark matter and reveals strong association between membranome and CRISPR-Cas systems.Science advances · 2023Article
- Review
- The ESKAPE mobilome contributes to the spread of antimicrobial resistance and CRISPR-mediated conflict between mobile genetic elements.Nucleic acids research · 2023Article
- Conceptual model to informFrontiers in cellular and infection microbiology · 2023Review
- Whole-Genome Analysis ofMolecules (Basel, Switzerland) · 2022Article
- CRISPR-Cas in Acinetobacter baumannii Contributes to Antibiotic Susceptibility by Targeting EndogenousMicrobiology spectrum · 2022Article
- Diversity and dynamics of the CRISPR-Cas systems associated with Bacteroides fragilis in human population.BMC genomics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
The ESKAPE pathogens (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.